EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC 3.0

Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients

Jinlin Hou, Edward Gane, Rozalina Balabanska, Wenhong Zhang, Jiming Zhang, Tien Huey Lim, Qing Xie, Chau-Ting Yeh, Sheng-Shun Yang, Xieer Liang, Piyawat Komolmit, Apinya Leerapun und 14 weitere

Clinical and Molecular Hepatology · 2024

DOI: 10.3350/cmh.2023.0422 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Clinical and Molecular Hepatology, 2024. Verfasst von Jinlin Hou und 25 weiteren Autor:innen. Beteiligte Einrichtung: Nanfang Hospital, Southern Medical University, Guangzhou, China. Hauptthemen laut MEDLINE: Antiviral Agents, Hepatitis B, Chronic, Imidazoles, Pyrazines. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Bristol Myers Squibb, Johnson & Johnson, AbbVie.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Aims: Four-week treatment of linvencorvir (RO7049389) was generally safe and well tolerated, and showed anti-viral activity in chronic hepatitis B (CHB) patients. This study evaluated the efficacy, safety, and pharmacokinetics of 48-week treatment with linvencorvir plus standard of care (SoC) in CHB patients.

Methods

This was a multicentre, non-randomized, non-controlled, open-label phase 2 study enrolling three cohorts: nucleos(t)ide analogue (NUC)-suppressed patients received linvencorvir plus NUC (Cohort A, n=32); treatment-naïve patients received linvencorvir plus NUC without (Cohort B, n=10) or with (Cohort C, n=30) pegylated interferon-α (Peg-IFN-α). Treatment duration was 48 weeks, followed by NUC alone for 24 weeks.

Results

68 patients completed the study. No patient achieved functional cure (sustained HBsAg loss and unquantifiable HBV DNA). By Week 48, 89% of treatment-naïve patients (10/10 Cohort B; 24/28 Cohort C) reached unquantifiable HBV DNA. Unquantifiable HBV RNA was achieved in 92% of patients with quantifiable baseline HBV RNA (14/15 Cohort A, 8/8 Cohort B, 22/25 Cohort C) at Week 48 along with partially sustained HBV RNA responses in treatment-naïve patients during follow-up period. Pronounced reductions in HBeAg and HBcrAg were observed in treatment-naïve patients, while HBsAg decline was only observed in Cohort C. Most adverse events were grade 1–2, and no linvencorvir-related serious adverse events were reported.

Conclusions

48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiviral AgentsHepatitis B, ChronicImidazolesPyrazinesHumansCapsidDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensHepatitis B virusPolyethylene GlycolsRNAStandard of CareTreatment Outcome

Stichwörter der Autor:innen

Capsid assembly modulatorChronic hepatitis BLinvencorvirPhase 2RO7049389

Substanzen

Antiviral AgentsDNA, ViralHepatitis B e AntigensHepatitis B Surface AntigensImidazoleslinvencorvirPolyethylene GlycolsPyrazinesRNA

Autor:innen und Institutionen

  • Nanfang Hospital, Southern Medical University, Guangzhou, China.
  • New Zealand Liver Transplant Unit, The University of Auckland, Auckland, New Zealand.
  • Acibadem City Clinic Tokuda Hospital EAD, Sofia, Bulgaria.
  • Huashan Hospital, Fudan University, Shanghai, China.
  • Middlemore Hospital, Auckland, New Zealand.
  • Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.

Förderung

  • Bristol Myers Squibb
  • Johnson & Johnson
  • AbbVie
  • Aligos Therarpeutics
  • AiCuris
  • Antios Therapeutics
  • Arrowhead Pharmaceuticals
  • Arbutus Biopharma

Zitieren

APA

Hou, J., Gane, E., Balabanska, R., Zhang, W., Zhang, J., Lim, T. H., Xie, Q., Yeh, C. T., Yang, S. S., Liang, X., Komolmit, P., Leerapun, A., Xue, Z., Chen, E., Zhang, Y., Xie, Q., Chang, T. T., Hu, T. H., Lim, S. G., …, & Yuen, M. F. (2024). Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2023.0422

Vancouver

Hou J, Gane E, Balabanska R, Zhang W, Zhang J, Lim TH, et al. Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients. Clinical and Molecular Hepatology. 2024. doi:10.3350/cmh.2023.0422

BibTeX
@article{Hou2024,
  author = {Hou, Jinlin and Gane, Edward and Balabanska, Rozalina and Zhang, Wenhong and Zhang, Jiming and Lim, Tien Huey and Xie, Qing and Yeh, Chau-Ting and Yang, Sheng-Shun and Liang, Xieer and Komolmit, Piyawat and Leerapun, Apinya and Xue, Zenghui and Chen, Ethan and Zhang, Yuchen and Xie, Qiaoqiao and Chang, Ting-Tsung and Hu, Tsung-Hui and Lim, Seng Gee and Chuang, Wan-Long and Leggett, Barbara and Bo, Qingyan and Zhou, Xue and Triyatni, Miriam and Zhang, Wen and Yuen, Man-Fung},
  title = {Efficacy, safety, and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients},
  journal = {Clinical and Molecular Hepatology},
  year = {2024},
  doi = {10.3350/cmh.2023.0422}
}
Kostenlos starten →